EP-1277: Optimising RT dose for anal cancer - the development of three clinical trials in one platform
Year: 2017
Type: conference-abstract
Abstract: ResultsDose escalation radiotherapy treatment reports a benefit in pCR (9.5 % vs 20 % p= 0.029), tumoral downstaging rate (42.7 % vs 60% p=0.020), nodal downstaging rate (62.9% vs 7.7% p= 0.173) and ypT0 rate (10.3% vs 20 p= 0.049).Complete microscopical resection increses on integrated boost group (93.4% vs 98% statistically non-significant).In the comparison between both groups by Contingency Table , no statistically significant differences were found on toxicity (G2 27.5% vs 37%; G3 3.1 % vs 9%) or surgical complications (35.7% vs 40%).With a follow up of 181 months, the study reports a statistically significance on disease free survival (56.1% vs 76.7 % p= 0.036 Kaplan-Meier Test), and overall survival (21% vs 46.65 p=0.02) in the SIB group.Locorregional recurrence-free survival also improves but without statistical significance (88% vs 94.9 % Kaplan-Meir method).Tumoral downstaging was considered as an independent factor on DFS (HR 1.914 p=0.004Cox model.)Conclusion Escalation dose radiotherapy group achieved statistical differences in pCR (ypT0 yN0), tumoral downstaging rate, overall survival (OS) and distant disease free survival (DFS).pCR could be considered as a prognostic factor on OS.The variable tumoral downstaging demonstrate a great value as an independent factor on DFS.
Source: Radiotherapy and Oncology
Authors: D. Sebag-Montefiore, R. Adams, S. Bell, L. Berkman, D. Gilbert, R. Glynne-Joones, V. Goh, W. Gregory, M. Harrison, L. Kachnic, M. Lee, L. McParland, R. Muirhead, B. O'Neil, G. Hutchins, S. Rao, A. Renehan, A. Smith, G. Velikova, M. Hawkins
Institution: Ospedale Cisanello
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,770
OpenAlex ID: W2735092106